Document is current
Any future updates will be listed below
-
Authors
Boeszoermenyi, Andras https://orcid.org/0000-0001-9810-7241
Radeva, Denitsa L.
Schindler, Sebastian https://orcid.org/0009-0008-6932-8203
Valadares, Veronica https://orcid.org/0000-0003-1931-3464
Padmanabha Das, Krishna M. https://orcid.org/0000-0002-0116-4256
Dubey, Abhinav https://orcid.org/0000-0002-2392-8050
Viennet, Thibault https://orcid.org/0000-0001-5349-0179
Schmitt, Max https://orcid.org/0009-0002-9328-7401
Kast, Peter https://orcid.org/0000-0002-0209-8975
Gelev, Vladimir M. https://orcid.org/0000-0003-4309-6762
Stoyanov, Nikolay
Burdzhiev, Nikola
Petrov, Ognyan
Ficarro, Scott
Marto, Jarred https://orcid.org/0000-0003-2086-1134
Geffken, Ezekiel A.
Dhe-Paganon, Sirano
Seo, Hyuk-Soo https://orcid.org/0000-0003-0646-2102
Alexander, Nathan D. https://orcid.org/0009-0004-2551-6094
Cooley, Richard B.
Mehl, Ryan A.
Kovacs, Helena https://orcid.org/0000-0002-5246-9439
Anklin, Clemens https://orcid.org/0000-0002-3421-8951
Bermel, Wolfgang
Kuprov, Ilya https://orcid.org/0000-0003-0430-2682
Takeuchi, Koh https://orcid.org/0000-0002-6227-4627
Arthanari, Haribabu https://orcid.org/0000-0002-7281-1289
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM136859, GM124165, RM1-GM144227, RM1-GM144227, RM1-GM144227)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI143565)
- License Information
-
More Information
Article History
Received: 1 May 2023
Accepted: 28 March 2025
First Online: 5 May 2025
Competing interests
: V.M.G. is the founder of FB Reagents Ltd., a company that provides isotopically enriched NMR reagents. C.A. works for Bruker BioSpin Corporation, which is a manufacturer of equipment used in this work. W.B. and H.K. were employees at Bruker BioSpin Corporation when this work was conducted and have since retired. H.A. is a co-founder of Quantum Therapeutics Inc., a company that employs computational methods for drug development, although the work presented here does not overlap with that of the company. The other authors declare no competing interests.
